NOXXON's Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference
NOXXON Pharma AG announced that Prof. Hermann Haller, Director of the Department of Nephrology and Hypertension at Hanno…
NOXXON Pharma AG announced that Prof. Hermann Haller, Director of the Department of Nephrology and Hypertension at Hanno…
NOXXON Pharma AG gab bekannt, dass Proof-of-Concept-Daten einer Phase-IIa-Studie mit Emapticap Pegol (NOX-E36) in diabet…
NOXXON Pharma AG announced that Phase IIa proof-of-concept data from the emapticap pegol (NOX-E36) trial in diabetic nep…